Aalto Bio Reagents Recombinant Yellow Fever Virus Protein

Aug 02, 2017

Irish-based Aalto Bio Reagents announced its first-to-market recombinant Yellow Fever Virus (YFV) protein for diagnostic test manufacturers, vaccine developers, and researchers. The protein will satisfy an urgent need for a specific and sensitive serological VFV assay in tropical and subtropical countries in South America and Africa, where co-circulation with other flaviviruses is high, the company said. The polyhistidine-tag, recombinant protein is expressed in HEK293 cells and is derived from strain 17D. The mosquito-borne disease is normally difficult to diagnose, as cross-reaction with other flavivirus infections is common. Laboratory diagnosis is accomplished by means of serological testing for the detection of during the postviremic phase of VFV. There are no validated IgM ELISA kits commercially available at present, and in order for VFV infection to be confirmed by serological techniques, a differential diagnosis with other flavivirus infections must be carried out.

More Like This

Oct 23, 2017

MNG Laboratories RNA Sequencing Tests

MNG Laboratories has launched several diagnostic RNA sequencing services for patients with neurogenetic disorders. Three types of tests are available, all with turnaround times of two to four weeks: MNG Transcriptome, which provides complete transcriptome sequencing; gene-specific RNA sequencing, which includes up to five genes for investigating previously identified variants of unknown significance; and panel-specific RNA sequencing, which analyzes the expression of all genes in an NGS panel that was ordered at the same time. The tests have been validated in blood; fibroblast, muscle, and lymphoid cell lines; and nervous and brain tissue.  

Oct 19, 2017

Tempus xT Cancer Genome Sequencing Panel

Tempus has introduced Tempus xT, a genome sequencing panel that analyzes 595 genes related to diagnosis, prognosis, and therapeutic targeting of cancer. Among other things, the panel looks for single-nucleotide variants, small insertions and deletions, amplifications of copy numbers, and structural alterations that could cause fusions, the company said. Chicago-based Tempus will run the xT panel at its own next-generation sequencing lab.

Oct 16, 2017

IGeneX Lyme Disease and Tick-Borne Relapsing Fever Tests

IGeneX, a CLIA and New York-approved reference lab, launched three new tests for diagnosing Lyme disease and Tick-Borne Relapsing Fever, also known as TBRF. The Lyme ImmunoBlot IgM and IgG tests are inclusive for detection of most species of B. burgdorferi, which is one of the two groups of Borrelia that causes disease. The TBRF ImmunoBlots IgM and IgG tests are designed to detect antibodies to specific antigens of TBRF Borrelia in human serum, specifically antibodies to B. hermsii, B. miyamotoi, B. turicatae, and B. coriaceae. The Lyme IGXSpot test is an enzyme-linked immunoSpot, also known as an ELISPOT assay, which detects human T cells reactive to B. burgdorferi specific antigens.

Oct 16, 2017

Theradiag, Miraca Life Sciences Therapeutic Drug Monitoring

In vitro diagnostics and theranostics firm Theradiag said its partner Miraca Life Sciences will start marketing an eighth therapeutic drug monitoring test from Theradiag's Lisa Tracker range in the US.

Under a technology licensing agreement, Miraca will market the test, starting early in November, under the name InformTx.

Theradiag noted that an InformTx report provides clinicians with quantitative test results, historical test result data, and guidance from the most up-to-date peer-reviewed scientific literature. Testing measures the level of a specified drug as well as patient-derived antibodies to the specified drug. Miraca Life Sciences uses laboratory-validated ELISA technology for InformTx therapeutic drug monitoring, and test results are reported within five days.

Oct 16, 2017

Prometheus Laboratories NASH, Crohn's and Inflammatory Bowel Diagnostics

Prometheus Laboratories introduced three new laboratory diagnostic products aimed at nonalcoholic steatohepatitis, or NASH, Crohn’s Disease, and adult inflammatory bowel disease. The FibroSpect NASH test is designed to help clinicians stratify NASH patients by risk based on the severity of their liver fibrosis. The noninvasive serum test was validated with well-characterized and clinically confirmed NASH patients.

The Prometheus Monitr Crohn’s Disease is a serum test for measuring and monitoring serum status in Crohn’s disease patients. Traditionally, Crohn’s Disease has only been diagnosed invasively through colonoscopy and endoscopy.  The Monitor Crohn’s Disease, which can be used as an adjunct to endoscopy or by itself between endoscopies, demonstrated high accuracy and concordance rates with endoscopically visual mucosal disease during clinical validation, Prometheus said.  

The Prometheus Anser UST is a drug-monitoring test for use with adult inflammatory bowel disease patients treated with Stelara, also known as ustekinumab. As a drug-tolerant test, Prometheus Anser UST measures both serum drug concentrations and antidrug antibody levels from a single serum sample to help physicians monitor this biologic therapy and optimize treatment.

Oct 12, 2017

GenePOC Group B Streptococcus Direct Swab

GenePOC launched its Group B Streptococcus Direct Swab molecular test in Europe. The assay is for use on Revogene, the firm's microfluidic real-time PCR instrument, and will help minimize the risk of GBS transmission from mother to baby. It also will help to optimize antibiotic stewardship, said GenePOC, a member of the Debiopharm Group. 

Oct 11, 2017

Hamamatsu NanoZoomer S360

Hamamatsu launched the NanoZoomer S360 high-throughput whole slide imaging scanner. The instrument has a capacity of 360 slides and can deliver fast scanning of 82 slides per hour. It also has an intelligent slide management feature that uses custom barcode labels for personalizing specific scanning parameters to prioritize and scan different tissues with minimal user-scanner interaction. 

Oct 10, 2017

Cyrex Laboratories Array 14 Mucosal Immune Reactivity Screen

Clinical immunology laboratory Cyrex Laboratories launched the Array 14 Mucosal Immune Reactivity Screen, which can assess mucosal immune reactivity in saliva by measuring salivary secretory immunoglobulin A and M. Mucosal production of IgA and IgM antibodies may be an early event in immune reactivity to dietary proteins, bacterial toxins, and tissue antigens, Cyrex said. 

Oct 09, 2017

Fast Track Diagnostics Enteric Fever Kit

Fast Track Diagnostics has launched a kit to detect the pathogens that cause enteric fever, also known as typhoid or paratyphoid fever. The FTlyo Enteric fever kit includes blood collection tubes containing a proprietary Salmonella enrichment broth, ready-to-use multiplex PCR for detection of Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi, and an internal control. The reagents required for the PCR are lyophilized in single-patient sample tubes that can be stored at room temperature, and clinicians need only add extracted nucleic acids to begin the eight-hour detection workflow.

Oct 09, 2017

Sysmex America CyFlow antibodies,

Sysmex America introduced CyFlow antibodies, analyte-specific reagent antibodies for flow cytometry applications. The launch marks Sysmex's entrance into the clinical flow cytometry market, the firm said, adding they can be used on any flow cytometer platform, allowing pathology labs to use the clone with the highest quality for their laboratory-developed tests. 

Oct 06, 2017

Xifin LIS Anywhere NGS Module

Xifin has added a next-generation sequencing model to its LIS Anywhere laboratory information system to support precision medicine. The new module, which will be on display at the College of American Pathologists annual meeting, is intended to help labs build their molecular diagnostics capabilities and improve genomics workflow.

Oct 05, 2017

Sysmex America XN-9100, XN-3100

Sysmex America launched the XN-9100 and XN-3100 hematology automation systems. The new systems combines the unified mechanization of earlier instrument models and has new features to provide labs with greater customization and scalability. For example, both systems integrate the new Sp-50, fifth-generation slidemaker-stainer, enhancing automation, improving both consistency and lab efficiency. 

Oct 05, 2017

Qiagen QuantiFeron-TB Gold Plus

Qiagen is launching the QuantiFeron-TB Gold Plus test in the US. It is the fourth generation of the blood-based test for tuberculosis infection, and was approved by the US Food and Drug Administration in June. The immunoassay detects the release of interferon-gamma as a proxy for latent tuberculosis infection. The newest generation adds CD8 antigens and workflow improvements that allow for more efficient implementation, especially in large-scale TB screening programs. The test will be available in the US starting Oct. 9 and was already available in 75 other countries in Europe, the Middle East, Africa, Asia, and Latin America, Qiagen said. 

Oct 05, 2017

ResearchDx, Menarini Silicon Biosystems DEPArray HER2

ResearchDx and Menarini Silicon Biosystems jointly launched DEPArray HER2, a FISH-based laboratory-developed test performed by PacificDx, a wholly owned subsidiary of ResearchDx. The test leverages cell isolation capabilities of DEPArray NxT technology, enabling pure tumor cell populations to be isolated from heterogeneous tumor/normal tissue samples.

Oct 04, 2017

DiaSorin group C and group G Streptococcus Primer Pairs

DiaSorin Molecular launched the primer pairs, group C and group G Streptococcus for use in laboratory-developed molecular tests. Classified as analyte-specific reagents, they can be used by high-complexity labs to develop their own LDTs.